کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3840096 | 1247889 | 2015 | 16 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
cfDNALMDERαAISMBCPGRDCISNGSLBDgDNAMGBHER2ddPCRER-positivecell-free DNA - DNA بدون سلولgenomic DNA - DNA ژنومیER+ - ER +FFPE - MEPlaser microdissection - microdissection لیزر لیزرstable disease - بیماری پایدارprogressive disease - بیماری پیشرفتهNext generation sequencing - توالی نسل بعدیligand-binding domain - دامنه اتصال لیگاندMetastatic breast cancer - سرطان متاستاتیک سینهIpsilateral breast tumor recurrence - عود مجدد تومور پستان در سمت راستDroplet digital polymerase chain reaction - قطره واکنش زنجیره ای پلیمراز دیجیتالAromatase inhibitors - مهار کننده های آراماتازformalin-fixed paraffin embedded - پارافین ثابت فرمالین تعبیه شده استPartial response - پاسخ جزئیMinor groove binding - پیوند کوچک جاروبرقیDuctal carcinoma in situ - کارسینوم داکتال در محلAndrogen Receptor - گیرنده آندروژنیEstrogen receptor α - گیرنده استروژن αHuman epidermal growth factor receptor 2 - گیرنده عامل فاکتور رشد اپیدرمی انسان 2hormone receptor - گیرنده هورمونProgesterone receptor - گیرنده پروژسترون
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
پزشکی و دندانپزشکی (عمومی)
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens](/preview/png/3840096.png)
چکیده انگلیسی
Droplet digital polymerase chain reaction (ddPCR), which could perform thousands of PCRs on a nanoliter scale simultaneously, would be an attractive method to massive parallel sequencing for identifying and studying the significance of low-frequency rare mutations. Recent evidence has shown that the key potential mechanisms of the failure of aromatase inhibitors-based therapy involve identifying activating mutations affecting the ligand-binding domain of the ESR1 gene. Therefore, the detection of ESR1 mutations may be useful as a biomarker predicting an effect of the treatment. We aimed to develop a ddPCR-based method for the sensitive detection of ESR1 mutations in 325 breast cancer specimens, in which 270 primary and 55 estrogen receptor-positive (ER+) metastatic breast cancer (MBC) specimens. Our ddPCR assay could detect the ESR1 mutant molecules with low concentration of 0.25 copies/μL. According to the selected cutoff, ESR1 mutations occurred in 7 (2.5%) of 270 primary breast cancer specimens and in 11 (20%) of 55 ER+ MBC specimens. Among the 11 MBC specimens, 5 specimens (45.5%) had the most common ESR1 mutation, Y537S, 4 specimens (36.3%) each had D538G, Y537N, and Y537C. Interestingly, 2 patients had 2 ESR1 mutations, Y537N/D538G and Y537S/Y537C, and 2 patients had 3 ESR1 mutations, Y537S/Y537N/D538G. Biopsy was performed in heterochrony in 8 women twice. In 8 women, 4 women had primary breast cancer and MBC specimens and 4 women had 2 specimens when treatment was failure. Four of these 8 women acquired ESR1 mutation, whereas no ESR1 mutation could be identified at first biopsy. ddPCR technique could be a promising tool for the next-generation sequencing-free precise detection of ESR1 mutations in endocrine therapy resistant cases and may assist in determining the treatment strategy.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Translational Research - Volume 166, Issue 6, December 2015, Pages 540-553.e2
Journal: Translational Research - Volume 166, Issue 6, December 2015, Pages 540-553.e2
نویسندگان
Takashi Takeshita, Yutaka Yamamoto, Mutsuko Yamamoto-Ibusuki, Toko Inao, Aiko Sueta, Saori Fujiwara, Yoko Omoto, Hirotaka Iwase,